



Press & News Releases

Release: **IMMEDIATE**
Contact: **Amber Gordon**
 Sterling Phillips
 (703) 329-9400

For: **HADRON, INC.**
 (Symbol: HDRN)

HADRON SUBSIDIARY AWARDED \$2.6 MILLION ANTHRAX RESEARCH CONTRACT BY THE UNITED STATES ARMY MEDICAL RESEARCH AND MATERIEL COMMAND

Alexandria, VA, March 22, 2001 -- Hadron, Inc. (OTC BB: HDRN) today announced that its Advanced Biosystems, Inc. subsidiary has been awarded a \$2.6 million, one-year contract by the U.S. Army Medical Research and Materiel Command to study and develop new medical defenses for anthrax.

This contract is a major step in Advanced Biosystems' multi-phase program to develop defenses against, and treatments for, specific biological agents that may be used in warfare or terrorist attacks. This research will develop innovative medical approaches to treating anthrax, including methods of enhancing antibiotic therapies, modulating the host immune response, and new methods to battle anthrax sepsis and septic shock.

Advanced Biosystems' President, Dr. Ken Alibek, said, "The research program funded by this contract will explore promising alternatives to the present medical defense approaches to anthrax. These new alternatives are based on a new view of anthrax etiology and pathogenesis." Sterling E. Phillips, Jr., Hadron's President and Chief Executive Officer, added, "We are pleased that Hadron has been chosen to perform this research, in an area so important to our national security. Contracts such as this are key to the aggressive growth potential we see in developing novel treatment and prophylactic approaches for many other biological threat agents that could be used in biological warfare and terrorism."

HADRON specializes in developing innovative technical solutions for the intelligence community, analyzing and supporting defense systems (including intelligent weapons systems and biological weapons defense), and supporting complex computer systems. The Company's stock trades on the OTC Electronic Bulletin Board under the symbol HDRN. HADRON can be found on the Internet at www.hadron.com. HADRON investor relations can be contacted at (703) 329-9400 or via email at agordon@hadron.com.

Except for the historical information contained herein, this press release contains forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, that involve a number of risks and uncertainties. These forward-looking statements may be identified by reference to a future period by use of forward-looking terminology such as "anticipate," "expect," "could," "intend," "may" and other words of similar nature. There are certain important factors and risks that could cause results to differ materially from those anticipated by the statements contained herein. Such factors and risks include business conditions and growth in the information services, engineering services, software development and government contracting arenas and in the economy in general. Competitive factors include the pressures toward consolidation of small government contracts into larger contracts awarded to major, multi-national corporations; and the Company's ability to continue to recruit and retain highly skilled technical, managerial and sales/marketing personnel. Other risks may be detailed from time to time in the Company's filings with the Securities and Exchange Commission. Hadron undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

#